Open AccessCentral nervous system relapse in a pediatric anaplastic large cell lymphoma patient with CLTC/ALK translocation treated with alectinib: A case report
Author(s) -
Jing Yang,
Jun Li,
Weiyue Gu,
LJ Jin,
Yanlong Duan,
Shuang Huang,
Meng Zhang,
XiSi Wang,
Yi Liu,
Chunju Zhou,
Chao Gao,
Huyong Zheng,
Yonghong Zhang
Publication year - 2020
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v8.i9.1685
Subject(s) - alectinib , anaplastic lymphoma kinase , medicine , lymphoma , chemotherapy , alk inhibitor , anaplastic large cell lymphoma , vincristine , cancer research , pathology , gastroenterology , lung cancer , malignant pleural effusion , cyclophosphamide
The aberrant expression of the anaplastic lymphoma kinase ( ALK ) gene in ALK-positive (ALK+) anaplastic large cell lymphoma (ALCL) is usually due to t(2;5)/NPM-ALK. However, rarely, aberrant ALK expression can also result from a rearrangement of the ALK gene with various partner genes. Central nervous system (CNS) metastasis is very rare in ALK+ALCL. Patients with CNS involvement show an inferior prognosis.